As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
7 Analysts have issued a Ensysce Biosciences Inc forecast:
7 Analysts have issued a Ensysce Biosciences Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 4.49 4.49 |
2%
2%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
|
| EBIT (Operating Income) EBIT | -11 -11 |
75%
75%
|
|
| Net Profit | -11 -11 |
38%
38%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on proprietary technology platforms to develop safer prescription drugs. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms, are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company is headquartered in La Jolla, CA.
| Head office | United States |
| CEO | D. Kirkpatrick |
| Employees | 8 |
| Founded | 2003 |
| Website | ensysce.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


